MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Hospital Morales Meseguer](/img/noimage_org.png)
Hospital Morales Meseguer
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (3)
2017
-
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Tumor Biology, Vol. 39, Núm. 6
-
Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
European Journal of Cancer, Vol. 75, pp. 73-82
2014
-
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248